Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

171.66 -1.04 (-0.60%)
Streaming Delayed Price Updated: 11:06 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
News headline image
Inflation, What Inflation? ↗
We typically have a song or two in our heads. After all, watching ticks is musical and has a lot of different beats. And typically, those songs turn into parodies. 
Via Talk Markets
News headline image
Global Stocks: Breaking Out? ↗
The S&P 500 is attempting to clear what has been an insurmountable trendline dating back to January 2022. 
Via Talk Markets
News headline image
The 3 Best Biotech Stocks Under $1 to Buy for January ↗
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
News headline image
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
News headline image
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to 
Via Benzinga
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
News headline image
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro ↗
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
News headline image
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Small Caps Vs Large Caps: Who Is Leading? ↗
Clearly, large-cap stocks have been leading with the Dow Jones down the last year to date, but even though the selling pressure has been constant, trading volume has been anemic. 
Via Talk Markets
News headline image
Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades' ↗
The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun 
Via Benzinga
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs... 
Via TheNewswire.com
Topics Stocks
News headline image
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
By Faith Ashmore, Benzinga 
Via News Direct
News headline image
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
News headline image
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients ↗
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. 
Via Benzinga
News headline image
Will The Dow Jones Continue Higher? Will The Nasdaq Follow? ↗
It's been a volatile few weeks in the markets, and it can be hard to tell if we're currently in a risk-on or risk-off environment. 
Via Talk Markets
News headline image
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead ↗
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets. 
Via Talk Markets
News headline image
Market Currents: Why Pick Stocks? ↗
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... 
Via Talk Markets
News headline image
Look Who’s Leading Now ↗
All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow. 
Via Talk Markets
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Can Biotech Stocks Continue Rallying In This Bear Market? ↗
Via Talk Markets
News headline image
October Was Not So Scary After All - Things To Keep A Watch Out For ↗
Via Talk Markets
News headline image
These 4 ETFs Feature on CNBC's 'Final Trades' ↗
On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq 
Via Benzinga
News headline image
Russell 2000: How Money Is Made And Lost In Small Caps ↗
IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength. 
Via Talk Markets
News headline image
The Four Indices: Where Each Are In A 4-Year Cycle ↗
In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger... 
Via Talk Markets
News headline image
Steady As She Goes With Healthcare Stocks ↗
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
News headline image
Precarious Action In The Bonds And Stock Market ↗
Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh? 
Via Talk Markets
News headline image
Taking The Temperature Of The Major Sector ETFs ↗
One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness. 
Via Talk Markets
News headline image
3 Technical Lessons On Whether Or Not Semiconductors Bottomed ↗
The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last. 
Via Talk Markets
News headline image
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
News headline image
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market ↗
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.